Jenburkt Pharmaceuticals Share Price

  • 1,141.9521.75 (1.94%)
  • Volume: 3,124
BSE
  • Closed
  • Last Updated On: 29 Aug, 2024, 03:51 PM IST
STOCK SCORE
ETPrime Only
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • TECHNICALS
  • COMPARE
Loading...

Jenburkt Pharmaceutical...

  • 1,141.9521.75 (1.94%)
  • Volume: 3,124
Advertisment

Jenburkt Pharma share price insights

View All

  • Company has become debt free for the first time since last 5 years. (Source: Standalone Financials)

  • Company has spent less than 1% of its operating revenues towards interest expenses and 29.93% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)

  • Stock gave a 3 year return of 125.06% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)

  • Stock generated 125.06% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)

  • Jenburkt Pharmaceuticals Ltd. share price moved up by 1.94% from its previous close of Rs 1,120.20. Jenburkt Pharmaceuticals Ltd. stock last traded price is 1,141.95

    Share PriceValue
    Today/Current/Last-1,141.95
    Previous Day-1,120.20

InsightsJenburkt Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		17.98
    EPS - TTM
    (₹)    		63.50
    MCap
    (₹ Cr.)    		503.98
    Sectoral MCap Rank
    		91
    PB Ratio
    (x)    		3.41
    Div Yield
    (%)    		1.34
    Face Value
    (₹)    		10.00
    Beta

    Beta

    1 Month1.69
    3 Months0.91
    6 Months0.83
    1 Year0.75
    3 Years0.77

    		1.69
    VWAP
    (₹)    		1,119.39
    52W H/L
    (₹)
    1,198.00 / 586.90

    Jenburkt Pharma Share Price Returns

    1 Day1.94%
    1 Week3.36%
    1 Month22.19%
    3 Months28.95%
    1 Year62.2%
    3 Years125.06%
    5 Years166.97%

    ET Stock ScreenersTop Score Companies

    Check whether Jenburkt Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Jenburkt Pharma News & Analysis

    View all Jenburkt Pharma Share News & Announcements

    Jenburkt Pharma Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Jenburkt Pharma Share Recommendations

    No Recommendations details available for this stock.
    Check out other stock recos.

    Jenburkt Pharma Financials

    • Income (P&L)

    • Balance Sheet

    • Cash Flow

    • Ratios

    • Insights

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 29.93% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)
      Quarterly | AnnualJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
      Total Income33.9440.0337.0139.3830.21
      Total Income Growth (%)-15.218.18-6.0430.36-17.12
      Total Expenses23.7729.6129.0929.7822.71
      Total Expenses Growth (%)-19.731.76-2.2931.12-19.74
      EBIT10.1810.427.919.617.50
      EBIT Growth (%)-2.3731.76-17.6728.05-8.04
      Profit after Tax (PAT)7.427.885.407.325.37
      PAT Growth (%)-5.9145.85-26.1936.37-15.50
      EBIT Margin (%)29.9826.0421.3824.4024.84
      Net Profit Margin (%)21.8519.6914.6018.5917.77
      Basic EPS (₹)16.8017.8612.2516.5912.17
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue146.63141.87128.93113.60123.11
      Total Revenue Growth (%)3.3610.0413.49-7.72-2.34
      Total Expenses111.46109.0199.0691.96101.97
      Total Expenses Growth (%)2.2510.047.72-9.822.57
      Profit after Tax (PAT)25.9824.6122.3016.5014.87
      PAT Growth (%)5.5710.3635.1110.98-24.89
      Operating Profit Margin (%)24.9624.3024.4420.2318.22
      Net Profit Margin (%)18.2917.9917.9815.0912.50
      Basic EPS (₹)58.8653.9048.5835.9632.40

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Profit & Loss Statement are available.

    • Insights

      • All Debts Paid-off

        Company has become debt free for the first time since last 5 years. (Source: Standalone Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets165.10141.81142.95120.38104.07
      Total Assets Growth (%)16.42-0.8018.7515.671.22
      Total Liabilities20.1619.4225.5721.9124.07
      Total Liabilities Growth (%)3.81-24.0516.70-8.97-5.09
      Total Equity144.94122.39117.3898.4780.00
      Total Equity Growth (%)18.424.2719.2023.093.27
      Current Ratio (x)6.705.143.574.464.52
      Total Debt to Equity (x)0.000.020.050.040.04
      Contingent Liabilities16.5719.5516.6116.4816.61

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Balance Sheet are available.

    • Insights

      • Cash from Operations vs PAT

        Operating cash flow of Rs 8.12 cr is 0.31 times compared to the reported net profit of Rs 25.98 cr. (Source: Standalone Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities8.1217.059.4018.0315.02
      Net Cash used in Investing Activities-0.582.62-1.33-18.78-2.88
      Net Cash flow from Financing Activities-7.08-21.04-5.530.71-10.83
      Net Cash Flow0.47-1.372.54-0.041.31
      Closing Cash & Cash Equivalent4.133.665.032.492.53
      Closing Cash & Cash Equivalent Growth (%)12.72-27.26101.76-1.59106.55
      Total Debt/ CFO (x)0.000.140.620.210.23

      All figures in Rs Cr, unless mentioned otherwise

      View Details

      No reported Cash Flow Statement are available.

    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)17.9220.1018.9916.7518.58
      Return on Capital Employed (%)23.8326.3624.9021.5825.70
      Return on Assets (%)15.7317.3515.5913.7014.28
      Interest Coverage Ratio (x)139.5996.7174.1346.6941.22
      Asset Turnover Ratio (x)0.930.960.9490.79114.24
      Price to Earnings (x)11.7211.9511.6711.099.81
      Price to Book (x)2.102.402.221.861.82
      EV/EBITDA (x)5.966.836.735.383.82
      EBITDA Margin (%)26.6125.9525.9722.0920.15

      No reported Financial Ratios are available.

    Financial InsightsJenburkt Pharma

    • Income (P&L)
    • Balance Sheet
    • Cash Flow

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 29.93% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)

      • All Debts Paid-off

        Company has become debt free for the first time since last 5 years. (Source: Standalone Financials)

      • Cash from Operations vs PAT

        Operating cash flow of Rs 8.12 cr is 0.31 times compared to the reported net profit of Rs 25.98 cr. (Source: Standalone Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Jenburkt Pharma Peer Comparison

    • Jenburkt Pharma Stock Performance

    • Ratio Performance

      • CHART
      • TABLE

      Insights

      • Stock Returns vs Nifty Smallcap 100

        Stock gave a 3 year return of 125.06% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)

      • Stock Returns vs Nifty Pharma

        Stock generated 125.06% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Insights

          • Stock Returns vs Nifty Smallcap 100

            Stock gave a 3 year return of 120.75% as compared to Nifty Smallcap 100 which gave a return of 92.43%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 120.75% return as compared to Nifty Pharma which gave investors 64.81% return over 3 year time period. (as of last trading session)

          Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Jenburkt Pharma17.983.4817.9223.8315.738.7924.9618.2958.866.700.000.00
          Lyka Labs600.787.74-3.653.66-1.588.573.92-2.35-0.791.350.8432.36
          Ambalal Sarabhai42.663.624.148.862.27-1.787.554.830.741.160.339.56
          Venus Remedies16.470.965.848.174.542.567.434.7321.314.530.081.11
          SMS Lifesciences Ind24.852.295.148.132.324.986.532.0630.081.070.554.02
          Add More
          Annual Ratios (%)

          Choose from Peers

          • POCL Enterprises
          • Zenotech Lab
          • Medico Remedies
          • Panchsheel Org
          • Fredun Pharma

          Choose from Stocks

            See All Parameters

          Peers InsightsJenburkt Pharma

          • Stock Returns vs Nifty Smallcap 100

            Stock gave a 3 year return of 125.06% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 125.06% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)

          Do you find these insights useful?

          • hate it

          • meh

          • love it

          Jenburkt Pharma Shareholding Pattern

          • QOQ Change

          • Total Shareholdings

          • Loading...
            Showing Jenburkt Pharma Shareholding as on 30 Jun 2024
            Category30 Jun 202431 Mar 202431 Dec 202330 Sep 2023
            Promoters46.7147.2347.3947.42
            Pledge0.000.000.000.00
            FII0.000.000.001.38
            DII0.000.000.000.00
            Mutual Funds0.000.000.000.00
            Others53.2952.7752.6151.19
          • Showing Shareholding as on 30 Jun 2024
            CategoryNo. of SharesPercentage% Change QoQ
            Promoters20,61,45046.71 %-0.51
            Pledge00.00 %0.00
            FII60,7321.38 %-0.41
            Others22,91,11853.29 %0.51

          MF Ownership

          MF Ownership details are not available.

          Top Searches:

          Jenburkt Pharma News Jenburkt Pharma Quarterly Results Jenburkt Pharma Dividend Jenburkt Pharma Q1 ResultsJenburkt Pharma Q2 ResultsJenburkt Pharma Q3 ResultsJenburkt Pharma Q4 Results

          Corporate Actions

          • Jenburkt Pharma Board Meeting/AGM

          • Jenburkt Pharma Dividends

          • Others
          • Meeting DateAnnounced onPurposeDetails
            Jul 26, 2024Jul 18, 2024Board MeetingQuarterly Results
            May 28, 2024May 21, 2024Board MeetingAudited Results & Dividend
            Feb 06, 2024Jan 19, 2024Board MeetingQuarterly Results
            Nov 07, 2023Oct 27, 2023Board MeetingQuarterly Results
            Aug 08, 2023Jul 25, 2023Board MeetingQuarterly Results
          • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
            Final153%15.3Jul 23, 2024May 28, 2024
            Final144%14.4Jul 19, 2023May 23, 2023
            Final120%12.0Jul 21, 2022May 27, 2022
            Final102%10.2Aug 30, 2021Jun 02, 2021
            Interim81%8.1Mar 18, 2020Mar 03, 2020

          • No other corporate actions details are available.

          About Jenburkt Pharma

          Jenburkt Pharmaceuticals Ltd., incorporated in the year 1985, is a Small Cap company (having a market cap of Rs 503.98 Crore) operating in Pharmaceuticals sector. Jenburkt Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2024. Show More

          • Executives

          • Auditors

          • AU

            Ashish U Bhuta

            Chairman & Managing Director
            AU

            Ashish U Bhuta

            Chairman & Managing Director
            DH

            Dilip H Bhuta

            WholeTime Director & CFO
            DH

            Dilip H Bhuta

            WholeTime Director & CFO
            Show More
          • D R Mehta & Associates

          Industry

          Pharma - Indian

          Key Indices Listed on

          -

          Address

          Nirmala Apartments,93, Jayprakash Road,Mumbai, Maharashtra - 400058

          Contact

          [email protected]

          http://www.jenburkt.com

          More Details

          Trending in Markets

          DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

          DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

          By using this site, you agree to the Terms of Service and Privacy Policy.

          Business News›Markets›Stocks›Stock Price Quotes›Jenburkt Pharma Share Price
          The Economic Times